Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. This phase 2, randomised, double-blind, placebo-controlled trial included healthy or medically stable individuals aged 18–85 years enrolled at two clinical...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet regional health. Western Pacific Vol. 29; p. 100586
Main Authors:	Hui, Ai-Min, Li, Jingxin, Zhu, Li, Tang, Rong, Ye, Huayue, Lin, Mei, Ge, Lei, Wang, Xiyuan, Peng, Fuzhong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Pan, Hongxing, Zhu, Jiahong, Song, Zhizhou, Qiu, Jingjun, Wang, Wei, Zheng, Jianfei, Ozhelvaci, Orkun, Shpyro, Svetlana, Bushway, Meghan, Derhovanessian, Evelyna, Kühnle, Marie-Cristine, Luxemburger, Ulrich, Muik, Alexander, Shishkova, Yoana, Khondker, Zakaria, Hu, Simin, Lagkadinou, Eleni, Şahin, Uğur, Türeci, Özlem, Zhu, Fengcai
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01.12.2022 Elsevier
Subjects:	BNT162b2 mRNA vaccine COVID-19 Internal Medicine Intramuscular injection Messenger RNA Neutralising antibodies Public Health SARS-CoV-2 Vaccination BNT162b2 mRNA vaccine COVID-19 SARS-CoV-2 Messenger RNA Vaccination Intramuscular injection Neutralising antibodies
ISSN:	2666-6065, 2666-6065
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!